Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to facilitate patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in four simple steps:
On March 14th 2017 QuiremSpheres® was used for the first time outside a research setting to treat a patient with metastatic colorectal cancer in the liver at the
Telephone: +31 85 0404170
E-mail: info.quirem@terumo-europe.com